Wyeth’s (WYE) shares are off 10% over the last three months, and trade near their 52-week low.
The stock is about to go lower. The company disclosed the receipt of an action letter from the (FDA) in response to the New Drug Application for bifeprunox, an antipsychotic that was reviewed for the acute treatment of schizophrenia, as well as the maintenance of stable adult patients
Last month the FDA declined to approve that company’s new antidepressant drug Pristiq.
It look like the beginning of a pattern.
Douglas A. McIntyre
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
